Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.

Eli Lilly chairman and CEO David Ricks joins 'Squawk on the Street' to discuss the path to becoming a trillion dollar company ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its ...

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...

Eli Lilly (LLY) says its weight-loss pill is on track to be approved in the US, lagging behind Novo Nordisk (NVO). Eli Lilly ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial ...